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Background and aims: Recent evidence suggests a key role of the local accumulation of diet-derived 
Advanced Glycation End-Products (AGEs) in evoking kidney injury/dysfunction associated with chronic 
exposure to hypercaloric diets. Pyridoxamine, a structural analog of vitamin B6 that exerts anti-glycative effect 
by interfering with oxidative macromolecular damage, is now in phase 3 clinical efficacy trial to delay chronic 
kidney diseases progression in patients with type 1 diabetes. However, so far, the potential beneficial 
renoprotective effects of pyridoxamine in type 2 diabetes and obesity have not yet been investigated. Thus, 
we aimed to study the role of dietary supplementation of piridoxamine as preventive strategy to counteract the 
deleterious renal effects evoked by hypercaloric diet in mice. 
Materials and methods: C57Bl/6J mice were fed a standard diet (SD, n = 16) or a diet enriched in fat (40%) 
and fructose (45%) (HFHF, n=16) for 12 weeks. At week 3, two subgroups of SD and HFHF mice started to 
receive pyridoxamine supplementation (150 mg/kg/day) in the drinking water. At week 12, mice were sacrificed 
and urine, plasma and kidneys were collected for Western blot, ELISA, histological and immunohistochemical 
analysis.  
Results: When compared to SD mice, HFHF fed mice showed increased body weight (25,2±1,1 vs. 33,7±2,1 
g, p<0,001) and impaired glucose homeostasis (fasting glycaemia 72,80±18,89 vs. 138,80±12,68 mg/dL, 
p<0.001).  Pyridoxamine administration significantly improved fasting glycaemia (104,60±9,71 mg/dL, p<0,05) 
but not body weight (34,7±3,5 g).  
Renal function was strongly impaired by hyper-caloric supplement (serum creatinine 0.70±0.06 vs 1.13±0.15 
mg/dL p<0.05; urine albumin 74.44±14.18 vs 265.07±15.43 g/mL, p<0.001) and, most notably, pyridoxamine 
significantly prevented the renal function derangements (serum creatinine 0.66±0.03, p<0.05 vs HFHF; urine 
albumin 195.28±34.68 g/mL, p<0.05 vs HFHF). Kidney morphology of HFHF fed mice presented strong 
vacuolar degeneration and loss of tubule brush border, both clearly attenuated by pyridoxamine administration. 
The HFHF-induced morphological and functional derangements were associated with a robust increase in the 
local expression of AGEs receptor (RAGE) and pro-fibrogenic markers (fibronectin, vimentin, SMAD2/3) as 
well as a significant activation of the pro-inflammatory NF-kB and Rho/ROCK signaling pathways. Interestingly, 
piridoxamine prevented the diet-induced overexpression of RAGE and pro-fibrogenic markers as well as the 
activation of the inflammatory signaling cascades. 
Conclusion: The present study demonstrated for the first time that the administration of the anti-glycative 
compound pyridoxamine reduced diet-dependent kidney injury and dysfunction by interfering with local AGEs 
accumulation, thus resulting in reduced activation of the pro-fibrotic and inflammatory cascades. 
 
 
